Observational registry data from patients with inflammatory bowel disease who contracted COVID-19 suggest a possible benefit from taking anti-TNF medication in terms of a composite outcome of death or hospital admission, however not with either outcome alone [134]. The gene discussed is TNF; the disease is COVID-19.